| 2024-11-19 |
Antibody-Drug Conjugates: Microtubule Inhibitors, DNA Binders, and Topoisomerase Inhibitors |
| 2024-10-28 |
What is ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity)? |
| 2024-10-24 |
What are Antibody-Drug Conjugates? |
| 2024-10-22 |
Week 4, October 2024: Further than ADCs? |
| 2024-10-22 |
The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapy |
| 2024-10-19 |
Antibody-Drug Conjugates (ADCs) and Drug–Antibody Ratio (DAR) |
| 2024-10-08 |
Week 2, October 2024: ADCs in Regulatory Review |
| 2024-10-06 |
Antibody-Drug Conjugates and Immune Checkpoint Inhibitors in Cancer Treatment |
| 2024-09-26 |
What is Antibody Drug Development? |
| 2024-09-13 |
What are Innovative Antibody Formats? |
| 2024-09-06 |
Antibody Effector Functions |
| 2024-08-26 |
Understanding the Difference Between ADC Biosimilars and ADC Isotypes |
| 2024-08-20 |
Precision In Vivo Research: How ADCs Make the Difference |
| 2024-08-13 |
Week 2, August 2024: Hepatitis B Virus (HBV) |
| 2024-08-07 |
BIO Asia 2024 – Taiwan: Highlights and Event Recap |
